




RealRate

PHARMACEUTICAL 2013

Affymax INC
Rank 158 of 218



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Affymax INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Affymax INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 5.7% points. The greatest weakness of Affymax INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 89% points.

The company's Economic Capital Ratio, given in the ranking table, is 136%, being 84% points below the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	102,510
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	99,075
Liabilities, Non-Current	799
Other Assets	12,726
Other Compr. Net Income	-20
Other Expenses	46,373
Other Liabilities	10,062
Other Net Income	43
Other Revenues	94,370
Property and Equipment	2,981
Research and Development	51,738
Selling, General and Administrative Expense	89,714

Output Variable	Value in 1000 USD
Assets	118,217
Liabilities	109,936
Expenses	187,825
Revenues	94,370
Stockholders Equity	8,281
Net Income	-93,412
Comprehensive Net Income	-93,422
BaseVar	255,206
ECR before LimitedLiability	-66%
Economic Capital Ratio	136%